Stay up to date on the latest information you need to devise benefit designs, make coverage decisions, and further value-based healthcare! Sign up for our newsletter or print publications today by entering your contact information below and clicking "Subscribe".

First Name *

Last Name *

Email Address *

Email Address (Verify) *

AHDB Print Edition

We will request your mailing address on the next page.

AHDB E-Newsletters & Communications

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.

In the United States, more than 80% of all patients with end-stage renal disease (ESRD) initiate dialysis with hemodialysis, and current reports indicate that this trend has changed little over the past 2 decades.

For much of modern history, physicians have made decisions about patient care by consulting their peers and by using rule-based approaches. Specialists have been consulted throughout history and became a necessity in the 1800s, as medicine became more complex.

End-stage renal disease (ESRD), also known as stage 5 kidney disease, is characterized by permanent kidney failure. Currently, more than 678,000 Americans have ESRD, and projections indicate that the population of patients with this disease may exceed 2 million by 2030.

Chronic noncancer pain is prevalent among US adults, costs approximately $600 billion annually, and can be especially burdensome for working-age adults because of lost productivity and the negative impact of this condition on a patient’s quality of life.

In a new study published in February 2018 in American Health & Drug Benefits, researchers have identified opioid prescription characteristics that may increase the patient’s risk for becoming a chronic user of opioid therapy.